Research methodology: cancer cachexia syndrome

被引:32
作者
Dahele, M [1 ]
Fearon, KCH [1 ]
机构
[1] Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland
关键词
cancer cachexia; physical activity; trials and end-points;
D O I
10.1191/0269216304pm906ra
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Cachexia is a syndrome and therefore does not have a specific definition. Patients are characterized by the presence of anorexia, early satiety, weight loss, weakness, anaemia and oedema. These features occur to a variable extent in different patients and may change in severity during the course of a patient's illness. The multifactorial origin of cachexia precludes a uniform pathophysiological definition. Taken together these factors have hindered clinical studies both at a fundamental level and in terms of the introduction of effective therapy. The advent of novel therapeutic targets (e.g., ubiquitin-proteasome pathway) and biological response modifiers has opened possibilities for new clinical trials in cachexia. Regulatory authorities feel it is important not only to demonstrate efficacy in terms of patients' nutritional status ( e. g., lean body mass) but also functional status ( e. g., performance status). This article reviews current methods to assess the latter. Methods focused on measuring physical activity level ( e. g., doubly labelled water technique or physical activity meters) promise objective data which can be readily interpreted in terms of clinically meaningful benefit.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 58 条
[11]   PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS [J].
DEWYS, WD ;
BEGG, C ;
LAVIN, PT ;
BAND, PR ;
BENNETT, JM ;
BERTINO, JR ;
COHEN, MH ;
DOUGLASS, HO ;
ENGSTROM, PF ;
EZDINLI, EZ ;
HORTON, J ;
JOHNSON, GJ ;
MOERTEL, CG ;
OKEN, MM ;
PERLIA, C ;
ROSENBAUM, C ;
SILVERSTEIN, MN ;
SKEEL, RT .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :491-497
[12]   CYTOKINES, THE ACUTE-PHASE RESPONSE, AND RESTING ENERGY-EXPENDITURE IN CACHECTIC PATIENTS WITH PANCREATIC-CANCER [J].
FALCONER, JS ;
FEARON, KCH ;
PLESTER, CE ;
ROSS, JA ;
CARTER, DC .
ANNALS OF SURGERY, 1994, 219 (04) :325-331
[13]  
FEARON KCH, 1988, CANCER RES, V48, P2590
[14]   Comorbidity and karnofksy performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies [J].
Firat, S ;
Byhardt, RW ;
Gore, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (02) :357-364
[15]  
FREDRIX EWHM, 1991, CANCER RES, V51, P6138
[16]   RESTING ENERGY-EXPENDITURE IN PATIENTS WITH NEWLY DETECTED GASTRIC AND COLORECTAL CANCERS [J].
FREDRIX, EWHM ;
SOETERS, PB ;
ROUFLART, MJJ ;
VONMEYENFELDT, MF ;
SARIS, WHM .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 53 (05) :1318-1322
[17]  
Greisinger AJ, 1997, CANCER PRACT, V5, P147
[18]   Timing of quality of life (QoL) assessments as a source of error in oncological trials [J].
Hakamies-Blomqvist, L ;
Luoma, ML ;
Sjöström, J ;
Pluzanska, A ;
Sjödin, M ;
Mouridsen, H ;
Ostenstad, B ;
Mjaaland, I ;
Ottosson, S ;
Bergh, J ;
Malmström, PO ;
Blomqvist, C .
JOURNAL OF ADVANCED NURSING, 2001, 35 (05) :709-716
[19]   Quality of life measurement in oncology -: a matter of the assessment instrument? [J].
Holzner, B ;
Kemmler, G ;
Sperner-Unterweger, B ;
Kopp, M ;
Dünser, M ;
Margreiter, R ;
Marschitz, I ;
Nachbaur, D ;
Fleischhacker, WW ;
Greil, R .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) :2349-2356
[20]   ELEVATED ENERGY-EXPENDITURE IN CANCER-PATIENTS WITH SOLID TUMORS [J].
HYLTANDER, A ;
DROTT, C ;
KORNER, U ;
SANDSTROM, R ;
LUNDHOLM, K .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (01) :9-15